In the past week, PACB stock has gone up by 27.66%, with a monthly gain of 56.40% and a quarterly surge of 53.57%. The volatility ratio for the week is 9.93%, and the volatility levels for the last 30 days are 11.71% for Pacific Biosciences of California Inc The simple moving average for the last 20 days is 34.02% for PACB stock, with a simple moving average of -57.11% for the last 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
Additionally, the 36-month beta value for PACB is 1.98. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PACB is 264.11M and currently, short sellers hold a 23.35% ratio of that float. The average trading volume of PACB on July 26, 2024 was 9.95M shares.
PACB) stock’s latest price update
The stock of Pacific Biosciences of California Inc (NASDAQ: PACB) has increased by 11.24 when compared to last closing price of 1.90. Despite this, the company has experienced a 27.66% gain in its stock price over the last five trading sessions. zacks.com reported 2024-07-24 that Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day’s close.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Jefferies repeating the rating for PACB by listing it as a “Buy.” The predicted price for PACB in the upcoming period, according to Jefferies is $4 based on the research report published on June 03, 2024 of the current year 2024.
Goldman gave a rating of “Neutral” to PACB, setting the target price at $2.50 in the report published on April 18th of the current year.
PACB Trading at 22.25% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.53% of loss for the given period.
Volatility was left at 11.71%, however, over the last 30 days, the volatility rate increased by 9.93%, as shares surge +50.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.07% lower at present.
During the last 5 trading sessions, PACB rose by +23.49%, which changed the moving average for the period of 200-days by -76.27% in comparison to the 20-day moving average, which settled at $1.6157. In addition, Pacific Biosciences of California Inc saw -78.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Farmer Michele, who sale 5,275 shares at the price of $2.03 back on May 20 ’24. After this action, Farmer Michele now owns 211,941 shares of Pacific Biosciences of California Inc, valued at $10,708 using the latest closing price.
Meline David W, the Director of Pacific Biosciences of California Inc, purchase 40,000 shares at $4.40 during a trade that took place back on Mar 06 ’24, which means that Meline David W is holding 40,000 shares at $176,160 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -1.61 for the present operating margin
- 0.24 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -1.48. The total capital return value is set at -0.2. Equity return is now at value -44.28, with -16.65 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.27. The debt to equity ratio resting at 1.39. The interest coverage ratio of the stock is -22.64.
Currently, EBITDA for the company is -277.67 million with net debt to EBITDA at -3.02. When we switch over and look at the enterprise to sales, we see a ratio of 7.09. The receivables turnover for the company is 6.61for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.28.
Conclusion
In conclusion, Pacific Biosciences of California Inc (PACB) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
